Q-omics provides the consensus-scored CSNK2B profile across patient tissues and cancer cell-line models. CSNK2B expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CSNK2B is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, CSNK2B RNA expression shows 18,951 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where CSNK2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSNK2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSNK2B survival associations across molecular data types. CSNK2B RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSNK2B RNA expression–survival associations across cancer types. High CSNK2B expression shows unfavorable associations in ACC, COAD, LIHC, SKCM and UCEC, but favorable associations in UVM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CSNK2B RNA expression.
This table summarizes CSNK2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CSNK2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSNK2B shows lower tumor expression in KICH and higher tumor expression in KIRC, LIHC, HNSC, LUAD and STAD. The KIRC box plot shows higher CSNK2B RNA expression in tumor versus normal tissue (log2 FC = +0.624, t-test p < 0.001).
This table shows molecular features associated with CSNK2B in patient tissues and cancer cell lines. In patient samples, CSNK2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CSNK2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
